Biogen halts development of Gosuranemab, therapy for rare brain disease

The therapy, Gosuranemab, failed to hit statistical significance in its main goal and did not demonstrate effectiveness on key secondary goals when tested in patients with progressive supranuclear palsy.

New Delhi: Biogen Inc said on Friday it would discontinue the development of its experimental therapy for a rare brain disease after it failed a mid-stage trial.

Read Also: Biogen builds case for its Alzheimers drug aducanumab, skeptics say more data needed

The therapy, Gosuranemab, failed to hit statistical significance in its main goal and did not demonstrate effectiveness on key secondary goals when tested in patients with progressive supranuclear palsy.

Read Also: Biogen to commercialize Samsung Bioepis 2 new ophthalmology biosimilars Lucentis, Eylea in major markets worldwide